All News

Exederm treats itching, inflammation, redness, and rash associated with eczema and dermatitis.

Lifitegrast ophthalmic solution (Xiidra) 5% is indicated for the treatment of the signs and symptoms of dry eye disease.

Glioblastoma can be very difficult to treat and a cure is often not possible.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.

With integrated specialty pharmacies enabling health systems to improve patient outcomes and lower total medical costs, every hospital will need a solution to support the growing number of patients on outpatient specialty medications.

Properly implemented CGMP should not be seen as a regulatory burden but a remedy to poorly compounded drugs.

Further, the Index is based on proprietary data from PCR testing services administered by Walgreens.

Clinical benefits were seen across subgroups, including patients with squamous and non-squamous lung cancer subtypes, and regardless of PD-L1 levels.

Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discussed what the impact of the pandemic has been on the advancement of data interoperability in health care.

The analysis describes cost-effective options for individuals without symptoms and recommends isolation strategies to help policymakers safeguard against resurgences.

Agency aims to allow electronic prescriptions for schedule II to V drugs between registered retail pharmacies on 1-time basis for initial fill.

Finding alternative means to promote interleukin 25 could enhance the benefits of fecal transplants in patients with recurrent C. difficile infections.

Cequa ophthalmic solution is indicated to increase tear production in patients with dry eyes.

Patients with Gilbert's syndrome are born with the condition because of an inherited gene mutation.

Patients can sometimes develop Guillain-Barre syndrome after having a recent respiratory illness or digestive tract infection and, in rare cases, after receiving certain vaccines.

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran, discussed the trial results assessing the efficacy and safety of inclisiran for patients with atherosclerotic cardiovascular disease.

Drug shortages, infrastructure and wholesaler challenges will be the backdrops of the pharmacy landscape this year.

Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discusses what data interoperability is and what it looks like within a pharmacy context.

Drug manufacturers participating in Medicaid offer lower prices, stretching resources and providing comprehensive services to more patients.

Continuing leadership education can help further develop pharmacy leaders by teaching effective utilization of various power strategies.

While progress is being made to advance the Cures Act, it is essential to ensure pharmacy interoperability given pharmacy’s critical role in health care.

The sBLA is reinforced by results from a randomized phase 3 trial that investigated cemiplimab-rwlc in combination with a physician’s choice of platinum-doublet chemotherapy compared to platinum-doublet chemotherapy alone.

The researchers projected that approximately 14 participants would experience a significant worsening of their walking function, however, only 8 participants had their walking function decline.

The Biden administration announced that it would make 400 million nonsurgical N95 masks for US citizens available free of charge at community health centers and retail pharmacies across the United States.

One viral protein could provide information to deter pneumonia causing the body’s exaggerated inflammatory response, new study results show.

Did trial court judge err when dismissing the lawsuit without direct evidence of plaintiff’s claim?

IMX-110 is a tissue-specific therapeutic designed to accumulate at intended therapeutic sites at 3 to 5 times the rate of conventional therapeutics.

The phase 3 ARASENS trial is the only study prospectively designed to evaluate an androgen receptor inhibitor combined with docetaxel and androgen deprivation therapy in this patient population.